Correction: Zealand Pharma: Significant Advancement of Clini

11.03.2022 - Company announcement – No. 9 / 2022 Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. Full Year Results for 2021 ...

Related Keywords

Denmark , United States , Oberland , Thün , Germany , Paris , France General , France , Copenhagen , Køavn , Netherlands , United Kingdom , Boston , Massachusetts , Amsterdam , Noord Holland , American , Emmanuel Dulac , David Rosen , Frank Sanders , Matt Dallas , Maeve Conneighton , Adam Steensberg , Zealand Pharma , Alexion Pharmaceuticals , European Commission , Boehringer Ingelheim , Drug Administration , American Diabetes Association , Obesity Society Annual Meeting , Jaeb Center , Research Development Corp , Astrazeneca , Health Research , Bionic Pancreas Pivotal Program , Amylin Analog , Track Designation , Development Corp , Chief Executive Officer , Pharmacy Benefit Managers , Managed Care Organizations , Wearable Insulin Delivery Devices , Bihormonal Artificial Pancreas , Beta Bionics , Let Bionic Pancreas Pivotal Program , Artificial Pancreas , Obesity Week , Astrazeneca Rare Disease , Annual Report , Chief Executive Officer Emmanuel Dulac , Senior Vice President , Chief Financial Officer Matt Dallas , Executive Vice President , Chief Medical Officer Adam Steensberg , Correction ,